Articles tagged "Hepatocellular carcinoma"

2021 American Transplant Congress
Albumin Level Prior to Liver-Directed Therapy is a Risk Factor of Waitlist Tumor Progression Independent of HCC Burden
P. Thevenot, K. Nunez, T. Sandow, M. Hibino, P. Wright, J. Patel, D. Fort, A. Cohen
Ochsner Health, New Orleans, LA
*Purpose: Milan Criteria, α-fetoprotein (AFP), and MELD score at diagnosis influence prognosis in bridge to transplant (BTT) hepatocellular carcinoma (HCC). With HCC surveillance many patients…
2021 American Transplant Congress
Improving Liver Transplantation Outcomes for Hepatitis C Associated Hepatocellular Carcinoma in Direct-Acting Antiviral Therapy Era
K. Okumura, H. Sogawa, G. Veillette, D. John, T. Diflo, R. Bodin, D. C. Wolf, S. Nishida
Surgery, Westchester Medical Center/New York Medical College, Valhalla, NY
*Purpose: Direct-acting antiviral (DAA) therapy has transformed the outcomes of liver transplantation(LT) in patients with hepatitis C virus (HCV). The aim of this study was…
2021 American Transplant Congress
Intrahepatic Spatial Location of HCC Recurrence Following Loco-regional Therapy for Solitary Tumors Predicts a Higher Oncologic Risk & Increased Recurrence Post-transplant
A. Mathur, E. Baughan, S. Haider, A. Griesemer, T. Kato, J. Emond
Columbia University, New York, NY
*Purpose: Loco-Regional therapy (LRT) for hepatocellular carcinoma (HCC) patients is an established bridge to Orthotopic Liver Transplantation (OLT). However, no large cohort data exist correlating…
2021 American Transplant Congress
The Role of Histone Acetylation/methylation Mediated Epigenetic Modifications in the Pathogenesis of Non-alcoholic Steatohepatitis-associated Liver Carcinogenesis
P. K. Rajan¹, U. Utibe-Abasi¹, J. D. Sanabria¹, M. Banerjee², G. Smith¹, M. S. Schade¹, J. Sanabria¹, K. Sodhi¹, S. Pierre², Z. Xie², J. I. Shapiro², J. Sanabria¹
¹Department of Surgery, Marshall University, Huntington, WV, ²Marshall Institute for Interdisciplinary Research (MIIR), Marshall University, Huntington, WV
*Purpose: Hepatocellular carcinoma (HCC) is one of the most aggressive human cancers and is characterized by an acquisition of multiple abnormal phenotypes driven by epigenetic…
2021 American Transplant Congress
Review of 10-Year Liver Explant Pathology Impact on Outcomes in a Single Center
Y. K. Kwon¹, L. Sher¹, S. Khemichian², J. Kahn², Y. Genyk¹
¹Hepatobiliary and Abdominal Transplant Surgery, University of Southern California, Los Angeles, CA, ²Gastrointestinal and Liver Diseases, University of Southern California, Los Angeles, CA
*Purpose: Explant pathology (EP) is an important prognostic factor after liver transplantation (LT) for hepatocellular carcinoma (HCC). The purpose of this study was to correlate…
2021 American Transplant Congress
Immunotherapy of Dc-cik Cells in Patient with Hepatocellular Carcinoma Recurrence Following Liver Transplantation
S. Hsu, L. Jeng, H. Yang, A. Thorat
China Medical University Hospital, Taichung, Taiwan
*Purpose: Dendritic cells (DCs) and cytokine-induced killer (CIK) cells, components of anti-cancer therapy, have shown clinical benefits and potential to overcome chemotherapeutic resistance in some…
2021 American Transplant Congress
Effects of TIPS on Transplant Outcomes for HCC
C. L. Hanlon¹, D. Toy¹, Y. Liu¹, S. Zhou¹, K. Zhou², J. Kahn², L. Yuan²
¹Internal Medicine, University of Southern California, Los Angeles, CA, ²Internal Medicine - Department of Gastroenterology and Hepatology, University of Southern California, Los Angeles, CA
*Purpose: The purpose of this study is to examine effects of TIPS placement on response to locoregional therapy (LRT) and clinical outcomes after liver transplantation…
2021 American Transplant Congress
Given the Potential Impact on Liver Transplant Selection, Revisiting the Current Standard of Diagnosis of Hepatocellular Carcinoma
K. Amarell, B. Fisher, B. Park, K. Ko, B. Kallakury
Department of Pathology & Laboratory Medicine, Georgetown University School of Medicine, Washington, DC
*Purpose: The current standard of diagnosis of hepatocellular carcinoma (HCC) relies on non-invasive radiographic methods, namely computerized tomography (CT) and/or magnetic resonance imaging (MRI). However,…
2021 American Transplant Congress
The Tumor-suppressor Signaling of the α1-na/k-atpase- Cav-1-src Complex at the Caveola in Nash Related Hepatocellular Carcinoma
U. S. Udoh¹, J. D. Sanabria¹, M. Banerjee¹, P. K. Rajan¹, M. Schade¹, J. A. Sanabria¹, A. Mallick¹, G. Smith¹, G. U. Udoh², K. Sodhi¹, S. Pierre², Z. Xie², J. Shapiro², J. Sanabria¹
¹Dept. of Surgery/ Marshall Institute for Interdisciplinary Research, Marshall University, Huntington,, WV, ²Marshall Institute for Interdisciplinary Research, Marshall University, Huntington,, WV
*Purpose: Hepatocellular Carcinoma (HCC) is the 2nd and fastest-growing cause of cancer related mortality worldwide, mainly from the metabolic cellular disturbances promoted by the epidemic…
2021 American Transplant Congress
Waitlist Outcomes for Patients with Hepatocellular Carcinoma Following the 2019 Exception Policy Change
K. Young¹, C. Enestvedt², W. Naugler¹, E. Maynard², A. Mitra¹, M. Wungiranirun¹, J. Jou¹, J. Ahn¹, M. Chang¹, D. Lhewa¹
¹Division of Gastroenterology and Hepatology, OHSU, Portland, OR, ²Division of Abdominal Organ Transplant, OHSU, Portland, OR
*Purpose: We aim to compare waitlist (WL) outcomes for HCC patients after the implementation of the most recent UNOS exception policy change on 5/1/2019.*Methods: All…

1
2
3
…
20
Next Page »